Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan

Yan, Jun; Wu, Shuang; Imazeki, Fumio; Yokosuka, Osamu

doi:10.1111/j.1872-034x.2012.01009.x

Cited by 17 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reasons for the varying rates of seropositivity are that these surveys were conducted in different regions, on different study populations and using diagnostic reagents of different sensitivities. In the current study, the result is similar to the prevalence of anti-HEV (21%) reported in a study of hepatitis E virus markers in Chinese people residing in Tokyo, Japan [37]. However, it is higher than the seropositive rate of 17.2% which was estimated in the Second National Viral Hepatitis Prevalence Survey in China in 1992 [32].…”

Section: Discussionsupporting

confidence: 88%

Epidemiology of Hepatitis E Virus in China: Results from the Third National Viral Hepatitis Prevalence Survey, 2005–2006

et al. 2014

View full text Add to dashboard Cite

In China, hepatitis E virus (HEV) is prevalent and causes disease, but its epidemiological profile is not well understood. We used a commercial enzyme-linked immunosorbent assay to detect total antibodies to hepatitis E virus in 15,862 serum samples collected during the Third National Viral Hepatitis Prevalence Survey. The results were analyzed to calculate estimates of HEV seroprevalence and to examine the effects of some putative risk factors. The seroprevalence of HEV in the general Chinese population during the period from 2005 through 2006 was 23.46% (95% confidence interval [CI], 18.41%–28.50%). The farming population, the age group of 15–60 year olds, and those living in the Midwest or Mideast region and in Xinjiang province had the highest seroprevalence estimates. The prevalence of HEV is high in China. The seroprevalence rate of HEV shows an unbalanced distribution among areas with different geographic location and economic development levels. The characteristics of the distribution associated may be due to the route of HEV transmission (via contaminated water or animal reservoirs). Within the same region, the seroprevalence of HEV is generally increased with age.

show abstract

Section: Discussionsupporting

confidence: 88%

Epidemiology of Hepatitis E Virus in China: Results from the Third National Viral Hepatitis Prevalence Survey, 2005–2006

et al. 2014

View full text Add to dashboard Cite

show abstract

“…It is known that HBV vaccine could induce anti-HBs in a majority of vaccinees [ 24 ]. Because there are no universal vaccination programs against HBV in Japan, HBV infections are still viewed as an important issue [ 25 ]. Then, we should consider recipients with anti-HBs as having experienced HBV infection, perhaps a setting different from other countries where universal vaccination programs against HBV exist.…”

Section: Discussionmentioning

confidence: 99%

Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment

Nakamoto

Nakaseko

Sakaida

et al. 2014

IJMS

Self Cite

View full text Add to dashboard Cite

We retrospectively reviewed 413 recipients with hematologic malignancies who underwent hematopoietic stem cell transplantation (HSCT) between June 1986 and March 2013. Recipients with antibody to hepatitis B core antigen (anti-HBc) and/or to hepatitis B surface antigen (anti-HBs) were regarded as experiencing previous hepatitis B virus (HBV) infection. Clinical data of these recipients were reviewed from medical records. We defined ≥1 log IU/mL increase in serum HBV DNA from nadir as HBV reactivation in hepatitis B surface antigen (HBsAg)-positive recipients, and also defined ≥1 log IU/mL increase or re-appearance of HBV DNA and/or HBsAg as HBV reactivation in HBsAg-negative recipients. In 5 HBsAg-positive recipients, 2 recipients initially not administered with nucleos(t)ide analogues (NUCs) experienced HBV reactivation, but finally all 5 were successfully controlled with NUCs. HBV reactivation was observed in 11 (2.7%) of 408 HBsAg-negative recipients; 8 of these were treated with NUCs, and fortunately none developed acute liver failure. In 5 (6.0%) of 83 anti-HBc and/or anti-HBs-positive recipients, HBV reactivation occurred. None of 157 (0%) recipients without HBsAg, anti-HBs or anti-HBc experienced HBV reactivation. In HSCT recipients, HBV reactivation is a common event in HBsAg-positive recipients, or in HBsAg-negative recipients with anti-HBc and/or anti-HBs. Further attention should be paid to HSCT recipients with previous exposure to HBV.

show abstract

“…Nineteen studies reported the prevalence of HCV infection in high-risk populations: ten were from China [17][18][19][20][21][22][23][24][25][26], two from Japan [27,28], two from Korea [29,30] and five from Taiwan [12,[31][32][33][34]. Among high-risk populations, the prevalence of HCV infection was higher among IDUs (48-95 % in China, Table 4).…”

Section: Prevalence Of Hcv Infection In High-risk Populationsmentioning

confidence: 96%

A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan

Bennett¹,

Waser²,

Johnston³

et al. 2015

Hepatol Int

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is associated with substantial clinical and economic burden and is an important public health issue in Asia. The objective of this review was to characterize HCV epidemiology and related complications in China, Japan, South Korea and Taiwan. A search of electronic databases and conference abstracts identified 71 potentially relevant articles. Of those, 55 were included in the epidemiology review and 9 in the review of HCV-related complications. HCV prevalence in the general population was 1.6% in China, 0.6-0.9% in Japan, 0.6-1.1% in South Korea and 1.8-5.5% in Taiwan. Prevalence was higher for injecting drug users (48-90%) and those with human immunodeficiency virus coinfection (32-85%) and was lower for blood donors (<1%). Annual incidence of HCV in China was 6.01 per 100,000. HCV genotype 1b was associated with the highest incidence of hepatocellular carcinoma (HCC). Five-year survival for patients with liver cirrhosis was 73.8%, decreasing to 39.2% following liver transplantation; the majority of deaths were attributable to HCC. Limitations were that the majority of studies included in the epidemiology review were small, regional studies conducted in specific populations, and there was an absence of large population-based studies. Thus, estimates may not be representative of the epidemiology of HCV for each country. The prevalence HCV in China and HCV incidence in the Asian region remain largely unknown, and they are likely underestimated. Further epidemiologic and clinical data are needed to provide more precise estimates for use by public health agencies.

show abstract

Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan

Abstract: Indigenous Japanese subjects have less immunity against HAV and HBV. The HBV carrier rate is higher in Chinese subjects, and attention should be paid to this issue in clinical practice. It might be important to control hepatitis viruses in Chinese subjects when doctors see them in Japan.

Cited by 17 publications

References 24 publications

Epidemiology of Hepatitis E Virus in China: Results from the Third National Viral Hepatitis Prevalence Survey, 2005–2006

Epidemiology of Hepatitis E Virus in China: Results from the Third National Viral Hepatitis Prevalence Survey, 2005–2006

Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment

A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan

Contact Info

Product

Resources

About